At the recently held 2024 Retina World Congress Meeting, Texas Retina’s Dallas Director of Clinical Research Ashkan M. Abbey, MD, presented topline results from the DAVIO 2 clinical trial investigating EYP-1901 (Duravyu), an investigational sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD) that combines vorolanib, a selective tyrosine kinase (anti-VEGF) inhibitor, with bioerodible Durasert E™.

Dr. Abbey shared that the Phase II clinical trial met its primary endpoint with both doses of the sustained-release implant tested demonstrating a statistically non-inferior change in best corrected visual acuity (BCVA) compared to aflibercept control. The drug also achieved a favorable safety profile with no EYP-1901-related ocular or systemic serious adverse events. Furthermore, the trial achieved its secondary endpoints with both EYP-1901 doses tested, including the following:

  • An over 80% reduction in treatment burden
  • Nearly two-thirds (64%) of patients not requiring supplemental injections six months after the injection
  • Strong anatomical control as measured by optical coherence tomography (OCT)

“We’re looking at the potential for a new therapy that allows us to treat and maintain our patients who are receiving anti-VEGF injections, helping them to possibly have a significant reduction in treatment burden with just one additional injection maybe every 6 to 9 months,” shared Dr. Abbey.

EyePoint Phramaceuticals, the maker of EYP-1901, hopes to launch its DAVIO Phase III clinical trial later this year, and Texas Retina plans to participate when the study opens.

Click here to watch a video of Dr. Abbey explaining the results of the DAVIO 2 trial.

Click here to access a list of Texas Retina’s current clinical trials.